Skip to content

US · IKT · BIOTECHNOLOGY

Inhibikase Therapeutics, Inc. (IKT) intrinsic value and stock valuation

$1.32as of 2026-11-21 · Mkt cap 326.12M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Inhibikase Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values IKT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IKT’s statements →

Inhibikase Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Wilmington, DE 19801 inhibikase.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$0.00
20162025
Net income
-$-48.26M
20162025
Free cash flow
-$-27.79M
20162025
Total equity
$172.9M+77.6% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$0.00$0.00$260K$120K$3.1M
Operating income-$-51.97M-$-28.59M-$-20.09M-$-18.13M-$-14.77M
Net income-$-48.26M-$-27.52M-$-19.03M-$-18.05M-$-14.79M
EPSd-$-490.9K-$-396.77K-$-3.57M-$-4.3M-$-4.88M
Operating cash flow-$-27.79M-$-19.15M-$-18.09M-$-17.35M-$-14.3M
Capital expenditure-$-10K$0.00-$-10K-$-240K$0.00
Free cash flow-$-27.79M-$-19.15M-$-18.1M-$-17.59M-$-14.3M
Total assets$181.2M$98.6M$14.5M$24.9M$42.5M
Total debt$0.00$110K$620K$350K$250K
Net debt-$-139.22M-$-56.38M-$-8.54M-$-6.84M-$-40.5M
Total equity$172.9M$94.9M$11M$21M$38.4M
Cash and short-term investments$178.8M$97.5M$13.3M$23.1M$40.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$260K$120K$3.1M
Cost of revenue$0.00$30K$13.6M$10K$11.4M
Gross profit$0.00-$-30K-$-13.36M$120K-$-8.26M
Research and development expenses$29.8M$17.2M$13.6M$12M$11.4M
Selling, general and administrative expenses$23.6M$11.4M$6.73M$6.21M$0.00
Other expenses-$-1.37M-$-30K-$-13.62M$0.00-$-4.85M
Operating expenses$52M$28.6M$6.73M$18.3M$6.51M
Cost and expenses$52M$28.6M$20.4M$18.3M$17.9M
Interest income$3.72M$1.07M$1.06M$70K$20K
Interest expense$0.00$0.00$0.00$70K$20K
Depreciation and amortization$60K$30K$180K$10K$14.8M
Ebitda-$-53.29M-$-27.49M-$-18.85M-$-18.05M$0.00
Operating income-$-51.97M-$-28.59M-$-20.09M-$-18.13M-$-14.77M
Total other income/expenses, net$3.72M$1.07M$1.06M$70K-$-20K
Income before tax-$-48.26M-$-27.52M-$-19.03M-$-18.05M-$-14.79M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-48.26M-$-27.52M-$-19.03M-$-18.05M-$-14.79M
Weighted average shares outstanding$98.3M$69.4M$5.33M$4.2M$3.03M
Weighted average diluted shares outstanding$98.3M$69.4M$5.33M$4.2M$3.03M
Balance sheet
20252024202320222021
Cash and short-term investments$178.8M$97.5M$13.3M$23.1M$40.8M
Net receivables$0.00$0.00$0.00$40K$110K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$180.1M$98.5M$14.2M$24.4M$42.5M
Property, plant and equipment, net$0.00$150K$300K$570K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.1M$150K$300K$570K$0.00
Total assets$181.2M$98.6M$14.5M$24.9M$42.5M
Accounts payable$1.16M$940K$650K$1.15M$1.09M
Short-term debt$0.00$110K$530K$150K$250K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.3M$3.73M$3.44M$3.7M$4.05M
Long-term debt$0.00$0.00$90K$210K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$90K$210K$0.00
Capital lease obligations$0.00$110K$240K$350K$0.00
Total liabilities$8.3M$3.73M$3.53M$3.9M$4.05M
Common stock$130K$70K$10K$0.00$30K
Retained earnings-$-142.68M-$-94.42M-$-66.9M-$-47.87M-$-29.82M
Accumulated other comprehensive income (loss)$20K-$-40K$0.00$100K$0.00
Total equity$172.9M$94.9M$11M$21M$38.4M
Total investments$39.5M$41.1M$4.09M$15.9M$0.00
Total debt$0.00$110K$620K$350K$250K
Net debt-$-139.22M-$-56.38M-$-8.54M-$-6.84M-$-40.5M
Cash flow statement
20252024202320222021
Net income-$-48.26M-$-27.52M-$-19.03M-$-18.05M-$-14.79M
Depreciation and amortization$60K$30K$180K$10K$0.00
Stock-based compensation$15.3M$8.14M$500K$460K$1.53M
Change in working capital$60K$200K$230K$170K-$-1.76M
Accounts receivable$0.00$0.00$40K$70K-$-110K
Inventory$0.00$0.00$0.00$0.00$1.3M
Accounts payable$150K$270K-$-500K$60K-$-630K
Net cash provided by operating activities-$-27.79M-$-19.15M-$-18.09M-$-17.35M-$-14.3M
Investments in property, plant and equipment-$-450K$0.00-$-10K-$-240K$0.00
Acquisitions, net$0.00$0.00$0.00$240K$0.00
Net cash used for investing activities$2.05M-$-37M$11.7M-$-16.01M$0.00
Common stock issued$108.5M$103.5M$8.54M$40K$41.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$108.5M$103.5M$8.41M-$-200K$41.1M
Net change in cash$82.7M$47.3M$1.98M-$-33.56M$26.8M
Cash at end of period$139.2M$56.5M$9.17M$7.19M$40.8M
Operating cash flow-$-27.79M-$-19.15M-$-18.09M-$-17.35M-$-14.3M
Capital expenditure-$-10K$0.00-$-10K-$-240K$0.00
Free cash flow-$-27.79M-$-19.15M-$-18.1M-$-17.59M-$-14.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Inhibikase Therapeutics, Inc.

        Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

        CEO
        Mark T. Iwicki
        Employees
        35
        Beta
        0.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Inhibikase Therapeutics, Inc. (IKT)?

        InvestorsCraft does not currently publish an intrinsic value for IKT. How the IC value is calculated.

        Is IKT undervalued?

        InvestorsCraft does not publish an undervaluation signal for IKT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.